Crescent Biopharma (CBIO) EBT (2013 - 2026)

Crescent Biopharma (CBIO) has reported EBT for 14 consecutive years, with -$24.8 million the latest figure, recorded in Q2 2026.

• On a quarterly basis, EBT fell 13.98% year-over-year to -$24.8 million in Q2 2026; TTM through Jun 2026 was -$163.1 million, a 214.76% decrease from a year earlier, with the FY2025 full-year figure at -$151.9 million, down 300.9% from the prior year.
• EBT was -$24.8 million for Q2 2026 at Crescent Biopharma, down from -$23.3 million in the prior quarter.
• Over five years, EBT peaked at -$2.3 million in Q1 2025 and troughed at -$90.4 million in Q4 2025.
• A 5-year average of -$17.7 million and a median of -$10.5 million in 2023 frame the typical range for EBT.
• Across the five-year window, EBT jumped 78.17% in 2025 and tumbled 893.41% in 2026, its largest moves.
• Over 5 years, EBT stood at -$10.2 million in 2022, then advanced by 11.38% to -$9.1 million in 2023, then sank by 96.8% to -$17.9 million in 2024, then sank by 405.94% to -$90.4 million in 2025, then jumped by 72.52% to -$24.8 million in 2026.
• The last three EBT figures came in at -$24.8 million (Q2 2026), -$23.3 million (Q1 2026), and -$90.4 million (Q4 2025), per Business Quant data.